Ito Tetsuhide, Jensen Robert T
Department of Medicine & Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20817, USA.
Int J Endocr Oncol. 2016;3(1):53-66. doi: 10.2217/ije.15.29. Epub 2016 Jan 18.
In multiple endocrine neoplasia type 1 (MEN1) patients, a number of recent studies compare the ability of different, new imaging modalities to existing modalities to localize the important neuroendocrine tumors (NETs) that contribute to their decreased life expectancy (pancreatic NETs [pNETs] and thymic carcinoids). These included the use of Ga-DOTATOC-PET/CT, endoscopic ultrasound and MRI. The current paper analyzes these results in light of current guidelines and controversies involved in the treatment/management of MEN1 patients. Particular attention is paid to results in these studies with thymic carcinoids and nonfunctional pNETs/gastrinomas, which recent studies show are particularly important in determining long-term survival. These studies show a number of promising imaging results but also raise a number of controversies, which will need to be addressed both in their use initially and for serial studies in these patients.
在1型多发性内分泌肿瘤（MEN1）患者中，最近的一些研究比较了不同的新型成像方式与现有成像方式定位导致患者预期寿命缩短的重要神经内分泌肿瘤（NETs）（胰腺NETs [pNETs]和胸腺类癌）的能力。这些成像方式包括使用镓标记的奥曲肽（Ga-DOTATOC）PET/CT、内镜超声和磁共振成像（MRI）。本文根据MEN1患者治疗/管理方面的现行指南和争议对这些结果进行了分析。特别关注了这些研究中胸腺类癌以及无功能pNETs/胃泌素瘤的结果，最近的研究表明这些在确定长期生存方面尤为重要。这些研究显示了一些有前景的成像结果，但也引发了一些争议，这些争议在这些成像方式的初始使用以及对这些患者的系列研究中都需要得到解决。
